此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项在不符合移植条件的新诊断骨髓瘤患者中比较两种治疗方法的试验 (KRdvsRd)

2026年9月17日 更新者:Fondazione EMN Italy Onlus

Carfilzomib - Lenalidmide - Dexamethasone (KRd) 与 Lenalidomi - Dexamethasone (Rd) 在新诊断的不符合自体干细胞移植条件的骨髓瘤患者中的比较:随机 III 期试验

The combination of lenalidomide plus low-dose dexamethasone (Rd) is considered the new standard for elderly newly diagnosed multiple myeloma (NDMM) patients. The combination carfilzomib plus lenalidomide-dexamethasone (KRd) in relapsed-refractory MM patients improved the progression-free survival (PFS) of approximately 1 year compared to standard Rd treatment. In a small phase 2 trial (23 pts) the KRd combination in elderly NDMM pts showed a complete response (CR) rate of 79% and a PFS at 3 years of 80%. Cardiovascular adverse events are the most limiting toxicities, especially in elderly patients.

研究概览

详细说明

This protocol is a randomized, multicenter study designed to determine the MRD negativity and the PFS of KRd treatment regimen.

Patients will be randomized in a 1:1 ratio to receive carfilzomib-lenalidomide-dexamethasone (KRd - Arm A) or lenalidomide-dexamethasone (Rd - Arm B).

Patients will be stratified basing on international staging system (ISS) and fitness status using a web-based procedure completely concealed to study participants.

All consecutive patients ≥ 65 years with newly diagnosed MM will be enrolled in a large randomized study during a period of 24 months.

Patients will be treated until disease progression or intolerance to the therapy. The only exception is for patients enrolled in KRd arm who achieve at least a VGPR during the first year of treatment and in sustained MRD negativity (MRD negative at least at 10-5 after one and two years of therapy): these patients will stop carfilzomib administration after 2 years, whereas treatment with lenalidomide and dexamethasone will be continued.

研究类型

介入性

注册 (实际的)

84

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Alessandria、意大利
        • AO "SS. Antonio e Biagio"
      • Ancona、意大利
        • AOU Ospedali Riuniti Umberto I
      • Ascoli Piceno、意大利
        • Ospedale Mazzoni
      • Bari、意大利
        • Policlinico di Bari
      • Bergamo、意大利
        • Ospedali Riuniti
      • Bolzano、意大利
        • Azienda Sanitaria di Bolzano - Ospedale Lorenz B:Ohler
      • Brescia、意大利
        • A.O. Spedali Civili di Brescia
      • Cagliari、意大利
        • Ospedale "A. Businco"
      • Candiolo、意大利
        • Istituto per la Cura e la RIcerca del Cancro di Candiolo
      • Cuneo、意大利
        • Ospedale Civico S. Croce e Carle
      • Florence、意大利
        • AOU Careggi
      • Meldola、意大利
        • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.)
      • Messina、意大利
        • Azienda Ospedaliera Papardo
      • Messina、意大利
        • Policlinico Universitario di Messina
      • Milan、意大利
        • ASST Grande Ospedale Metropolitano Niguarda
      • Milan、意大利
        • Istituto Europeo Oncologico
      • Milan、意大利
        • Istituto Nazionale Tumori
      • Milan、意大利
        • Ospedale Maggiore Policlinico di Milano
      • Naples、意大利
        • Università Federico II-Policlinico
      • Novara、意大利
        • Ospedale Maggiore
      • Orbassano、意大利
        • AO San Luigi Gonzaga
      • Padova、意大利
        • AO di Padova
      • Palermo、意大利
        • AO Cervello
      • Perugia、意大利
        • Ospedale S. Maria della Misericordia
      • Ravenna、意大利
        • Ospedale Santa Maria delle Croci
      • Reggio Calabria、意大利
        • AO Bianchi Melacrino Morelli
      • Reggio Emilia、意大利
        • Ausl-Irccs
      • Rimini、意大利
        • Ospedale Infermi
      • Rionero in Vulture、意大利
        • Ospedale Oncologico Regionale
      • Roma、意大利
        • Ospedale San Camillo Forlanini
      • Roma、意大利
        • Policlinico Umberto I - Università La Sapienza
      • Roma、意大利
        • ASL Roma 1
      • Roma、意大利
        • Azienda Ospedaliera Universitaria Policlinico Tor Vergata
      • Roma、意大利
        • Ospedale S. Eugenio - Università Tor Vergata
      • Rozzano、意大利
        • Istituto Clinico Humanitas
      • San Giovanni Rotondo、意大利
        • IRCCS Ospedale Casa Sollievo della Sofferenza
      • Terni、意大利
        • AO S. Maria
      • Torino、意大利
        • AOU Città della Salute e della Scienza di Torino - PO Molinette - Ematologia U
      • Torino、意大利
        • AOU Città della Salute e della Scienza di Torino - PO Molinette
      • Udine、意大利
        • Policlinico Universitario di Udine

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

65年 及以上 (年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Newly diagnosed symptomatic MM based on either standard CRAB criteria (at least 10% of clonal bone marrow plasma cells plus CRAB defined as the onset of any of the following clinical symptoms: hypercalcemia, renal failure, anemia and bone lesions) or at least 10% of bone marrow plasma cells plus the presence of at least one of the following biomarkers of malignancy:

    • 60% or greater clonal plasma cells on bone marrow examination;
    • Serum involved/uninvolved free light chain (FLC) ratio of 100 or greater;
    • More than one focal lesion on magnetic resonance imaging (MRI) that is at least 5 mm or greater in size.
  • Patient not eligible for ASCT (age ≥ 65 years or abnormal cardiac, pulmonary and liver function).

  • Patient defined as fit or intermediate according to the IMWG (International Myeloma Working Group) frailty score

  • Patient has given voluntary written informed consent.

  • Patient is able to be compliant with hospital visits and procedures required per protocol.

  • Patient agrees to use acceptable methods for contraception.

  • Patient has measurable disease according to IMWG criteria.

  • Patient has ECOG (Eastern Cooperative Oncology Group) performance status < 3.

  • Pre-treatment clinical laboratory values within 30 days before randomization:

    • Platelet count ≥50 x 109/L (≥30 x 109 /L if myeloma involvement in the bone marrow is > 50%)
    • Absolute neutrophil count (ANC) ≥ 1 x 109/L without the use of growth factors
    • Corrected serum calcium ≤14 mg/dL (3.5 mmol/L)
    • Alanine transaminase (ALT): ≤ 3 x the ULN
    • Total bilirubin: ≤ 2 x the ULN
    • Calculated or measured creatinine clearance: ≥ 30 mL/minute.
  • LVEF≥ 40%: 2-D transthoracic echocardiogram (ECHO) is the preferred method of evaluation; multigated Acquisition Scan (MUGA) is acceptable if ECHO is not available

  • Pre-treatment blood pressure value < 140/90 mmHg even with adequate therapy: 24 hours blood pressure monitoring is the preferred method of evaluation; blood pressure diary at home for 2 weeks is acceptable.

  • Females of childbearing potential (FBCP) comply with the conditions of the Pregnancy Prevention Plan, including confirmation that she has an adequate level of understanding.

  • FBCP must follow the Pregnancy Prevention Plan and use a highly effective and an additional barrier contraception method simultaneously for 4 weeks before starting therapy, during treatment and dose interruptions and for at least 30 days after the last dose of study drugs*

  • Males must use an effective barrier method of contraception if sexually active with FCBP during the treatment and for at least 90 days after the last administration of study drug/s. Male subjects must agree to refrain from sperm donation for at least 90 days after the last dose of carfilzomib.

Exclusion Criteria:

  • Serious medical condition, laboratory abnormality or psychiatric illness that prevented the subject from the screening or place the subject at unacceptable risk.

  • Patient defined as frail according to the IMWG frailty score.

  • Previous treatment with anti-myeloma therapy (does not include radiotherapy, bisphosphonates, or a single short course of steroid < to the equivalent of dexamethasone 40 mg/day for 4 days).

  • Pregnant or lactating females.

  • Presence of:

    • Clinical active infectious hepatitis type A, B, C or HIV
    • Acute active infection requiring antibiotics or infiltrative pulmonary disease
    • Pulmonary hypertension and interstitial lung disease
    • Uncontrolled arrhythmias or history of QT prolongation
    • Myocardial infarction or unstable angina ≤ 6 months or other clinically significant heart disease
    • Peripheral neuropathy or neuropathic pain grade 2 or higher, as defined by National Cancer Institute Common Toxicity Criteria (NCI CTC) 5.0 (Appendix A)
    • Uncontrolled hypertension defined as persistent hypertension (>140/90 mmHg) regardless treatment with 3 drugs, including a diuretic.
  • Contraindication to any of the required drugs or supportive treatments and hypersensitivity to any excipient of the study drugs.

  • Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib).

  • Invasive malignancy within the past 3 years.

  • Administration of any experimental drug within 4 weeks prior the baseline or within 5 drug half-lives.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:KRd (Experimental Arm)

Carfilzomib (K):

  • 20 mg/m2 IV on day 1 of cycle 1;
  • 56 mg/m2 IV on days 8 and 15 in cycle 1;
  • 56 mg/m2 IV on days 1, 8 and 15 in cycles 2-12;
  • 56 mg/m2 on days 1 and 15 from cycle 13 and onwards.

Lenalidomide (R):

- 25 mg orally on days 1-21 of each cycle.

Dexamethasone (d):

- 40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is a 28-day cycle.

Until PD or intolerance. Only patients that achieve at least a VGPR within the first year of treatment and in sustained MRD negativity (MRD negative at least at 10-5 after 1 and 2 years of therapy) will stop carfilzomib after 2 years of treatment, and will continue with lenalidomide and dexamethasone administration.

  • 20 mg/m2 IV on day 1 of cycle 1 enhanced to 56 mg/m2 on days 8, and 15 of cycle 1;
  • 56 mg/m2 IV on days 1, 8 and 15 in cycles 2-12;
  • 56 mg/m2 IV on days 1 and 15 from cycle 13 and onwards.
其他名称:
  • Kyprolis

- 25 mg orally on days 1-21 of each cycle.

其他名称:
  • 来那度胺

- 40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is to be repeated every 28 days. Patients that achieve at least a VGPR within the first year of study treatment and in sustained MRD negativity (MRD negative at least at 10-5 after 1 and 2 years of therapy) will stop carfilzomib administration after 2 years and will continue with lenalidomide and dexamethasone treatment until disease progression or intolerance to the therapy. Other patients will continue carfilzomib administration until disease progression or intolerance.

For patients >75 years of age, the dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each treatment cycle.

有源比较器:Rd (Control Arm)

Lenalidomide (R):

-25 mg orally on days 1-21 of each cycle.

Dexamethasone (d):

-40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is a 28-day cycles.

Until PD or intolerance.

- 25 mg orally on days 1-21 of each cycle.

其他名称:
  • 来那度胺

- 40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is to be repeated every 28 days. Patients that achieve at least a VGPR within the first year of study treatment and in sustained MRD negativity (MRD negative at least at 10-5 after 1 and 2 years of therapy) will stop carfilzomib administration after 2 years and will continue with lenalidomide and dexamethasone treatment until disease progression or intolerance to the therapy. Other patients will continue carfilzomib administration until disease progression or intolerance.

For patients >75 years of age, the dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each treatment cycle.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Minimal residual disease (MRD)
大体时间:5 years

1. Minimal residual disease (MRD): unit of measure is not applicable, MRD is expressed as a pure number

5 years
Progression-free survival (PFS)
大体时间:5 years

2. Progression-free survival (PFS): unit of measure is not applicable, PFS is expressed as a pure number

5 years

次要结果测量

结果测量
措施说明
大体时间
Rate of drug reduction or drug discontinuation
大体时间:5 years

Incidence of dose reduction and drug discontinuation in both treatment arms.

5 years
Cardiovascular assessment
大体时间:5 years

Benefit of proper cardiovascular baseline assessment and monitoring during treatment in both treatment arms:to mitigate major cardiovascular adverse event incidence, to prolong duration of treatment, to improve efficacy.

5 years
Rate of dose reduction, drug discontinuation and toxicities
大体时间:5 years

Safety as rate of dose reduction, drug discontinuation and toxicities

5 years
Response rate
大体时间:5 years

Response rate will include complete response (CR), very good partial response (VGPR) and partial response (PR) using the International Response Criteria. Responders are defined as subjects with at least a PR.

5 years
Progression-free survival 2 (PFS2)
大体时间:5 years

Time from randomization to objective tumor progression on next-line treatment or death from any cause.

5 years
Time to progression (TTP)
大体时间:5 years

Time to progression will be measured from the date of randomization to the date of first observation of PD, or deaths related to PD.

5 years
Duration of response (DOR)
大体时间:5 years

Time between first documentation of response and PD. Responders without disease progression will be censored either at the time of lost to FU, at the time of death due to other cause than PD, or at the end of the study.

5 years
Overall survival (OS)
大体时间:5 years

Time between randomization and death. Subjects who die will be censored at time of death as an event, regardless cause of death.

5 years
Time to next therapy (TNT)
大体时间:5 years

Time to next therapy will be measured from the date of randomization to the date of next anti-myeloma therapy. Death due to any cause before starting therapy will be considered an event.

5 years
MRD negativity
大体时间:5 years

Correlation between MRD negativity and PFS, PFS2, TTP, TNT and OS

5 years
Prognostic factors
大体时间:5 years

The following outcomes will be analysed in subgroups with different prognostic factors:

  • Progression-free survival (PFS),
  • Time to second disease progression (PFS2),
  • Time to progression (TTP),
  • Time to next therapy (TNT ),
  • Overall survival (OS)
5 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Sara Bringhen、A.O.U. Città della Salute e della Scienza

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2019年7月1日

初级完成 (估计的)

2027年9月1日

研究完成 (估计的)

2027年9月1日

研究注册日期

首次提交

2019年7月2日

首先提交符合 QC 标准的

2019年9月17日

首次发布 (实际的)

2019年9月19日

研究记录更新

最后更新发布 (实际的)

2026年9月21日

上次提交的符合 QC 标准的更新

2026年9月17日

最后验证

2026年9月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅